Akebia Therapeutics (AKBA) Cash & Equivalents (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Cash & Equivalents data on file, last reported at $162.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 43.39% year-over-year to $162.6 million in Q1 2026; TTM through Mar 2026 was $162.6 million, a 43.39% increase from a year earlier, with the FY2025 full-year figure at $184.8 million, up 256.36% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $162.6 million, down from $184.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for AKBA reached as high as $184.8 million in Q4 2025 and fell as low as $34.0 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $99.2 million across 5 years, with a median of $90.5 million in 2022.
• Across the five-year window, Cash & Equivalents tumbled 67.86% in 2023 and jumped 389.54% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $90.5 million in 2022, then sank by 52.55% to $42.9 million in 2023, then grew by 20.84% to $51.9 million in 2024, then jumped by 256.36% to $184.8 million in 2025, then slipped by 12.03% to $162.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $162.6 million in Q1 2026, $184.8 million in Q4 2025, and $166.4 million in Q3 2025.